BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 12527385)

  • 1. Control mechanism of JAK/STAT signal transduction pathway.
    Yamada S; Shiono S; Joo A; Yoshimura A
    FEBS Lett; 2003 Jan; 534(1-3):190-6. PubMed ID: 12527385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Curcumin suppresses Janus kinase-STAT inflammatory signaling through activation of Src homology 2 domain-containing tyrosine phosphatase 2 in brain microglia.
    Kim HY; Park EJ; Joe EH; Jou I
    J Immunol; 2003 Dec; 171(11):6072-9. PubMed ID: 14634121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of cytokines and JAK-STAT activation by distinct signaling pathways.
    Sengupta TK; Schmitt EM; Ivashkiv LB
    Proc Natl Acad Sci U S A; 1996 Sep; 93(18):9499-504. PubMed ID: 8790359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway.
    You M; Yu DH; Feng GS
    Mol Cell Biol; 1999 Mar; 19(3):2416-24. PubMed ID: 10022928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of SHP1 and up-regulation of negative regulators of JAK/STAT signaling in HTLV-1 transformed cell lines and freshly transformed human peripheral blood CD4+ T-cells.
    Cheng J; Zhang D; Zhou C; Marasco WA
    Leuk Res; 2004 Jan; 28(1):71-82. PubMed ID: 14630083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initiation and maintenance of CNTF-Jak/STAT signaling in neurons is blocked by protein tyrosine phosphatase inhibitors.
    Jiao J; Kaur N; Lu B; Reeves SA; Halvorsen SW
    Brain Res Mol Brain Res; 2003 Aug; 116(1-2):135-46. PubMed ID: 12941469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of interferon alfa signaling components in human alcoholic liver disease.
    Nguyen VA; Gao B
    Hepatology; 2002 Feb; 35(2):425-32. PubMed ID: 11826419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SOCS-1, -2, -3: selective targets and functions downstream of the prolactin receptor.
    Tomic S; Chughtai N; Ali S
    Mol Cell Endocrinol; 1999 Dec; 158(1-2):45-54. PubMed ID: 10630404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression.
    Schaper F; Gendo C; Eck M; Schmitz J; Grimm C; Anhuf D; Kerr IM; Heinrich PC
    Biochem J; 1998 Nov; 335 ( Pt 3)(Pt 3):557-65. PubMed ID: 9794795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein tyrosine phosphatase epsilonC selectively inhibits interleukin-6- and interleukin- 10-induced JAK-STAT signaling.
    Tanuma N; Shima H; Nakamura K; Kikuchi K
    Blood; 2001 Nov; 98(10):3030-4. PubMed ID: 11698287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway.
    Chim CS; Fung TK; Cheung WC; Liang R; Kwong YL
    Blood; 2004 Jun; 103(12):4630-5. PubMed ID: 14976049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SHP-2 regulates SOCS-1-mediated Janus kinase-2 ubiquitination/degradation downstream of the prolactin receptor.
    Ali S; Nouhi Z; Chughtai N; Ali S
    J Biol Chem; 2003 Dec; 278(52):52021-31. PubMed ID: 14522994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1.
    David M; Chen HE; Goelz S; Larner AC; Neel BG
    Mol Cell Biol; 1995 Dec; 15(12):7050-8. PubMed ID: 8524272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor.
    Bousquet C; Susini C; Melmed S
    J Clin Invest; 1999 Nov; 104(9):1277-85. PubMed ID: 10545526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppressors of cytokine signaling (SOCS): inhibitors of the JAK/STAT pathway.
    Cooney RN
    Shock; 2002 Feb; 17(2):83-90. PubMed ID: 11837794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway.
    O'Shea JJ; Gadina M; Schreiber RD
    Cell; 2002 Apr; 109 Suppl():S121-31. PubMed ID: 11983158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lymphoma: implications for epigenetic activation of the Jak/STAT pathway.
    Chim CS; Wong KY; Loong F; Srivastava G
    Leukemia; 2004 Feb; 18(2):356-8. PubMed ID: 14614518
    [No Abstract]   [Full Text] [Related]  

  • 18. The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation.
    Iwamoto T; Senga T; Naito Y; Matsuda S; Miyake Y; Yoshimura A; Hamaguchi M
    Oncogene; 2000 Sep; 19(41):4795-801. PubMed ID: 11032030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel SHP-1/Grb2-dependent mechanism of negative regulation of cytokine-receptor signaling: contribution of SHP-1 C-terminal tyrosines in cytokine signaling.
    Minoo P; Zadeh MM; Rottapel R; Lebrun JJ; Ali S
    Blood; 2004 Feb; 103(4):1398-407. PubMed ID: 14551136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of Janus kinase 2 by cisplatin in cancer cells.
    Song H; Sondak VK; Barber DL; Reid TJ; Lin J
    Int J Oncol; 2004 Apr; 24(4):1017-26. PubMed ID: 15010843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.